The IL-6–JAK–STAT3 pathway promotes survival, stemness, epithelial-to-mesenchymal transition (EMT), metabolic reshaping, and immunosuppression via induction of PD-L1 and myeloid recruitment programs, placing IL-6 at the nexus of cancer cell fitness and microenvironmental control [49]. The gene discussed is IL6; the disease is cancer.